U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Polymyxin B is a lipopeptide antibiotic isolated from Bacillus polymyxa. Its basic structure consists of a polycationic peptide ring and a tripeptide side chain with a fatty acid tail. Polymyxin B is a mixture of at least four closely related components, polymyxin B1 to B4, with polymyxin B1 and B2 being the two major components. Polymyxin B acts on Gram-negative bacteria by interacting with lipopolysaccharide (LPS) of the outer membrane and destabilizing it. Polymyxin B is indicated for the treatment of many bacterial diseases such as meningeal infections, urinary tract infections and bacteremia.

CNS Activity

CNS Active
4002
Curator's Comment: Polymyxin B penetrates BBB and cause neurotoxic effect.

Approval Year

1951
105
Targets

Targets

Primary TargetPharmacologyConditionPotency
Myosin light chain kinase, smooth muscle
6
Target ID: Q28824
Gene ID: 338037.0
Gene Symbol: MYLK
Target Organism: Bos taurus (Bovine)
Inhibitor
8504
 70.0 µM [IC50]
Protein kinase C (Bos taurus)
2
Target ID: Protein kinase C (Bos taurus)
Inhibitor
8504
 4.0 µM [IC50]
Inhibitor
8504
 800.0 µM [IC50]
Binding Agent
1076
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
Curative
Approved
8583
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
Curative
Approved
8583
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
Curative
Approved
8583
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
PubMed

PubMed

TitleDatePubMed
Polymyxin-B hemoperfusion in septic patients: analysis of a multicenter registry.
2016-12
Successful treatments with polymyxin B hemoperfusion and recombinant human thrombomodulin for fulminant Clostridium difficile-associated colitis with septic shock and disseminated intravascular coagulation: a case report.
2016-12
The effects of direct hemoperfusion using a polymyxin B-immobilized column in a pig model of severe Pseudomonas aeruginosa pneumonia.
2016-12
A feed-forward loop between SroC and MgrR small RNAs modulates the expression of eptB and the susceptibility to polymyxin B in Salmonella Typhimurium.
2016-11
Polymyxin B Nephrotoxicity: From Organ to Cell Damage.
2016
Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.
2015-11-13
Pharmacokinetics of intravenous polymyxin B in critically ill patients.
2008-11-15
Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria.
2008-10
Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria.
2008-10
COMPARISON OF THE ACTION OF STREPTOMYCIN, POLYMYXIN B, AUREOMYCIN AND CHLOROMYCETIN ON H. PERTUSSIS, H. PARAPERTUSSIS, H. INFLUENZAE AND FIVE ENTERIC STRAINS OF GRAM-NEGATIVE BACILLI.
1949-09
LABORATORY AND CLINICAL STUDIES OF POLYMYXIN B AND E.
1949-09
CHEMICAL STUDIES ON POLYMYXIN B.
1949-09
Patents

Patents

04661260
68
04771104
2

Sample Use Guides

In Vivo Use Guide
Curator's Comment: 25,000 to 30,000 units/kg/day (Intramuscular injection), 50,000 units once daily intrathecally for 3 to 4 days, then 50,000 units once every other day for at least 2 weeks (Intrathecal injection).
15,000 to 25,000 units/kg body weight/day
Route of Administration: Intravenous
In Vitro Use Guide
Polymyxin B MICs were determined for different strains of P. aeruginosa in Ca-MHB using a broth macrodilution method. The MIC was defined as the lowest concentration of drug that resulted in no visible growth after 24 h of incubation at 35°C in ambient air. The polymyxin B MIC ranged from 0.5 to 1 mg/liter.
Substance Class Mixture
Created
by admin
on Mon Mar 31 18:10:22 GMT 2025
Edited
by admin
on Mon Mar 31 18:10:22 GMT 2025
Record UNII
19371312D4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLOROMYXIN COMPONENT POLYMYXIN B SULFATE
Preferred Name English
Polymyxin B sulfate
GREEN BOOK   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Common Name English
STATROL COMPONENT POLYMYXIN B SULFATE
Common Name English
AEROSPORIN
Brand Name English
POLYMIXIN B SULFATE
Common Name English
PEDIOTIC COMPONENT POLYMYXIN B SULFATE
Common Name English
POLYMYXIN B SULFATE [USP MONOGRAPH]
Common Name English
OPHTHOCORT COMPONENT POLYMYXIN B SULFATE
Common Name English
OCUMYCIN COMPONENT POLYMYXIN B SULFATE
Common Name English
POLYMIXIN B SULFATE [JAN]
Common Name English
PYOCIDIN COMPONENT POLYMYXIN B SULFATE
Common Name English
MYCITRACIN COMPONENT POLYMYXIN B SULFATE
Common Name English
POLYMYXIN B, SULPHATE
Common Name English
OTOBIOTIC COMPONENT POLYMYXIN B SULFATE
Common Name English
NSC-757278
Code English
OTOBIONE COMPONENT POLYMYXIN B SULFATE
Common Name English
POLYTRIM COMPONENT POLYMYXIN B SULFATE
Common Name English
LANABIOTIC COMPONENT POLYMYXIN B SULFATE
Common Name English
Polymyxin b sulfate [WHO-DD]
Common Name English
POLYMYXIN B SULFATE [ORANGE BOOK]
Common Name English
POLYMYXIN B SULFATE [GREEN BOOK]
Common Name English
POLYMYXIN B, SULFATE
Common Name English
POLY-PRED COMPONENT POLYMYXIN B SULFATE
Common Name English
POLY-RX
Brand Name English
POLYMYXIN B SULPHATE
Common Name English
NEO-POLYCIN COMPONENT POLYMYXIN B SULFATE
Common Name English
POLYSPORIN COMPONENT POLYMYXIN B SULFATE
Common Name English
OTICAIR COMPONENT POLYMYXIN B SULFATE
Common Name English
OTOCORT COMPONENT POLYMYXIN B SULFATE
Common Name English
POLYMYXIN B SULFATE [EP MONOGRAPH]
Common Name English
MAXITROL COMPONENT POLYMYXIN B SULFATE
Common Name English
POLYMYXIN B SULFATE [USP IMPURITY]
Common Name English
POLYMIXIN B SULPHATE
Common Name English
POLYMYCIN B SULFATE
Common Name English
POLYMYXIN B SULFATE [USP-RS]
Common Name English
DEXACIDIN COMPONENT POLYMYXIN B SULFATE
Common Name English
DEXASPORIN COMPONENT POLYMYXIN B SULFATE
Common Name English
POLYMYXIN B SULFATE [VANDF]
Common Name English
POLYMYXIN B SULFATE [MI]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 333.120
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
NCI_THESAURUS C78160
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL1201283
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
EVMPD
SUB03938MIG
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
ECHA (EC/EINECS)
215-774-7
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
DAILYMED
19371312D4
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
RS_ITEM_NUM
1547007
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
NSC
757278
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
SMS_ID
100000090239
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
CAS
1405-20-5
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
EPA CompTox
DTXSID5045839
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
RXCUI
388
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY RxNorm
FDA UNII
19371312D4
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
MERCK INDEX
m8963
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB00781
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
NCI_THESAURUS
C61895
Created by admin on Mon Mar 31 18:10:22 GMT 2025 , Edited by admin on Mon Mar 31 18:10:22 GMT 2025
PRIMARY
All of the following components must be present:
Structure of POLYMYXIN B1 SULFATE
Structure of POLYMYXIN B1-I SULFATE
Structure of POLYMYXIN B3 SULFATE
Structure of POLYMYXIN B2 SULFATE
Related Record Type Details
POLYMYXIN B
ACTIVE MOIETY
Definition References
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966